StockData
Immuneering Corp logo

Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.71+0.04 (+1.09%)

Close on Nov 13, 2026Market cap $240.27MP/E –Yield –

Immuneering total assets

Total assets on the balance sheet at the end of each period.

Immuneering's total assets was $182.56M at Sep 30, 2026. For fiscal 2025 it was $231.99M, up 340.1% from the year before. The highest annual figure on record is $231.99M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$231.99M+340.1%
FY2024Dec 31, 2024$52.71M-48.6%
FY2023Dec 31, 2023$102.58M-16.2%
FY2022Dec 31, 2022$122.37M-26.6%
FY2021Dec 31, 2021$166.70M+333.9%
FY2020Dec 31, 2020$38.42M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$182.56M-24.3%
Q2 FY2026Jun 30, 2026$202.06M+404.4%
Q1 FY2026Mar 31, 2026$214.81M+323.8%
Q4 FY2025Dec 31, 2025$231.99M+340.1%
Q3 FY2025Sep 30, 2025$241.06M+251.6%
Q2 FY2025Jun 30, 2025$40.06M-48.0%
Q1 FY2025Mar 31, 2025$50.68M-42.4%
Q4 FY2024Dec 31, 2024$52.71M-48.6%
Q3 FY2024Sep 30, 2024$68.56M-39.8%
Q2 FY2024Jun 30, 2024$77.09M-38.3%
Q1 FY2024Mar 31, 2024$87.98M-18.3%
Q4 FY2023Dec 31, 2023$102.58M-16.2%
Q3 FY2023Sep 30, 2023$113.88M-14.8%
Q2 FY2023Jun 30, 2023$124.90M-12.1%
Q1 FY2023Mar 31, 2023$107.70M-29.4%
Q4 FY2022Dec 31, 2022$122.37M-26.6%
Q3 FY2022Sep 30, 2022$133.69M-18.5%
Q2 FY2022Jun 30, 2022$142.05M+167.8%
Q1 FY2022Mar 31, 2022$152.45M+296.8%
Q4 FY2021Dec 31, 2021$166.70M–
Q3 FY2021Sep 30, 2021$164.04M–
Q2 FY2021Jun 30, 2021$53.04M–
Q4 FY2020Dec 31, 2020$38.42M–

More Immuneering figures

See a number that looks wrong?